Evidence map›Paper›PMID 31467428›Full record

ArticleLeukemia2020

Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation.

Nicolas G Kint, Elien Heylen, Daniele Pepe, Kim De Keersmaecker, Catherine M Verfaillie, Michel Delforge

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicolas G KintDepartment of Internal Medicine-Hematology, University Hospitals Leuven, Leuven, Belgium. nicolas.kint@uzleuven.be.
Elien HeylenDepartment of Internal Medicine-Hematology, University Hospitals Leuven, Leuven, Belgium.
Daniele PepeLaboratory for Disease Mechanisms in Cancer, KU Leuven, Leuven, Belgium.
Kim De KeersmaeckerLaboratory for Disease Mechanisms in Cancer, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7420-9531
Catherine M VerfaillieStem Cell Institute Leuven, KU Leuven, Leuven, Belgium.
Michel DelforgeDepartment of Internal Medicine-Hematology, University Hospitals Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

3T3 CellsAnimalsAntineoplastic Combined Chemotherapy ProtocolsErythroid CellsFemaleHumansMaleMiceMiddle AgedMultiple MyelomaOligopeptidesProteasome InhibitorsReticulocytosisRetrospective StudiescarfilzomibOligopeptidesProteasome Inhibitors

Identifiers

PMID31467428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.